Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tedesco, Karen
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry	Active, not recruiting	N/A	3465	US	Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test	Biotheranostics, Inc.	Breast Cancer	12/28	12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37